The VERDICT Phase 4 trial shows that achieving corticosteroid-free disease clearance with vedolizumab in adults with moderate to severe ulcerative colitis significantly reduces time to first UC-related complication compared with reaching symptomatic remission alone (hazard ratio 0.33; 95% CI 0.17–0.67; P=0.0014).

Among those who reached their assigned targets, patients in disease clearance (Group 3) had a longer time to first UC-related complication than symptomatic remission (Group 1), while there was no significant difference between Groups 2 and 3, suggesting unclear incremental benefit of adding histologic remission beyond endoscopic remission for all patients.

The press release includes trial details (NCT04259138), context on UC burden, and safety information, with references to abstract presentations at UEG Week 2026 and Takeda’s role with ENTYVIO.

Exploratory molecular analyses identified proteomic and transcriptomic changes linked to early disease clearance, highlighting pathways related to inflammation, mucosal homeostasis, and tissue repair in bio-naïve patients achieving clearance by Week 16.

Limitations noted include that the primary analysis focused on those who achieved their assigned targets and the trial population was largely biologic-naive, which may limit generalizability.

Findings support treat-to-target strategies in UC and suggest disease clearance may be associated with better outcomes, but do not prove added benefit of targeting histologic remission beyond endoscopic remission for all patients.

VERDICT is the first prospective randomized UC trial to include disease clearance as a prespecified target, with results presented at UEG Week 2026 and published in the United European Gastroenterology Journal.

The trial demonstrates that achieving disease clearance is associated with a significantly reduced time to first UC-related complication (hazard ratio 0.33; 95% CI 0.17–0.67; P=0.0014) when using vedolizumab in moderate to severe UC.

Context emphasizes the importance of deeper remission beyond symptom relief for long-term outcomes in UC.

Safety through 96 weeks was consistent with prior ENTYVIO data, with no new safety signals and similar adverse event rates across groups.

VERDICT supports a treat-to-target approach aiming for deeper remission within 16 weeks, potentially altering the long-term course of UC treated with ENTYVIO.

By week 48, 400 participants (59.5%) achieved their assigned target, with 138 in group 3, 125 in group 2, and 137 in group 1; disease clearance combines symptomatic, endoscopic, and histologic remission.